PDCD1 and neoplasm: Further research finds that the interaction between the PD-1 expressed on monocytes and the PD-L1 on CLL cells impairs glycolysis, phagocytosis, and BTK signaling, contributing to tumor immune evasion and weakening immune-based therapy.